On 13 September 2017, the Technical Board of Appeal (TBA) of the European Patent Office (EPO) revoked the patent for Teva Pharmaceutical’s (Teva) synthesis of the active ingredient in Copaxone, a key drug used to treat recurring multiple sclerosis (MS). The case against Israel-based Teva was filed by the Netherlands-based generics and biopharmaceuticals company Synthon BV, who is now clear to market their generic glatiramer acetate in a number of European countries.
- Home
-
Generics
News
- US generics launch and approval for Dr Reddy’s and Lupin
- Five Chinese companies join UN’s MPP for Covid-19 medicines
- South Korean companies to make generic Bridion and COVID-19 drugs
- Revlimid (lenalidomide) generics launch across Europe
Research
- Community pharmacists’ understanding of generic and biosimilar drugs: Lebanon case study
- Reshaping landscape of Japanese generics market – uncertain future of universal health insurance
- Impact of e-bidding procurement on generic omeprazole injection prices in Thailand
- Trajectories of prices in generic drug markets
-
Biosimilars
News
- FDA approves Zymfentra and advances for Yuflyma in the US
- EC approval of natalizumab, aflibercept and tocilizumab biosimilars
- EMA recommends approval of first ustekinumab biosimilar Uzpruvo
- FDA approves first interchangeable ustekinumab biosimilar Wezlana
Research
- Biological therapies for psoriasis: evaluating durability and persistent benefits
- Switches between biosimilars and their reference products
- Latin America's biosimilars market: regulatory, institutional, and technological aspects
- Impact of trastuzumab biosimilars use in metastatic HER2-positive breast cancer
- MORE EDITORIAL SECTIONS
- Search
Post your comment